Impact of malignancy on laboratory parameters and survival in patients with pulmonary embolism

Selda Günaydın; Hayriye Bektaş Aksoy

Impact of malignancy on laboratory parameters and survival in patients with pulmonary embolism

Abstract

Aims: Pulmonary embolism (PE) is a life-threatening disease associated with significant morbidity and mortality, particularly in presence of malignancy. This study aimed to compare laboratory parameters with short-term and long-term mortality outcomes between malignant and non-malignant PE patients. Methods: In this retrospective study, 131 patients diagnosed with acute PE by computed tomography pulmonary angiography were included. Participants were divided into malignant (n=47) and non-malignant (n=84) groups. Demographic characteristics, laboratory parameters, and clinical findings were analyzed. The primary outcomes were 30-day and 365-day mortality, while secondary outcomes included 90-day and 180-day mortality. Results: Patients in the malignant group were younger and more frequently male (p<0.05). High-risk PE and right ventricular dysfunction were more common in the non-malignant group. White blood cell count, neutrophil count, and proBNP levels were significantly higher in non-malignant patients, whereas RDW levels were higher in the malignant group (p<0.05). There was no significant difference in 30-day mortality between groups (15.7% vs. 14.6%, p=0.869). Although 90-, 180-, and 365-day mortality rates were consistently higher in the malignant group, these differences were not statistically significant. Conclusion: While short-term mortality is similar between malignant and non-malignant PE patients, malignancy may be associated with an increased long-term mortality. Differences in laboratory and clinical features suggest that cancer-associated PE may represent a distinct clinical entity. These findings could contribute to more accurate risk stratification and the development of individualized treatment strategies.

Keywords

Ethical Statement

The study was conducted in accordance with the Declaration of Helsinki. Ethical approval for the study was obtained from the Ethics Committee of Giresun Training and Research Hospital (BAEK 2026/613 and Decision no: 04.03.2026/09).

References

Konstantinides SV, Meyer G, Becattini C, et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur Heart J. 2020;41(4):543-603. doi:10.1093/eurheartj/ehz405
Elshahaat HA, Zayed NE, Ateya MA, Safwat M, El Hawary AT, Abozaid MN. Role of serum biomarkers in predicting management strategies for acute pulmonary embolism. Heliyon. 2023;9(11):e21068. doi:10.1016/j.heliyon.2023.e21068
Fujieda K, Nozue A, Watanabe A, et al. Malignant tumor is the greatest risk factor for pulmonary embolism in hospitalized patients: a single-center study. Thromb J. 2021;19(1):77. doi:10.1186/s12959-021-00334-2
Aksoy İ, Akdemir HU, Tunçel ÖK. Investigation of the relationship of scube-1 and vap-1 levels on diagnosis, prognosis and clinical results in patients with pulmonary thromboembolism diagnosis in emergency department. Eurasian J Emerg Med. 2025;24(4):237. doi:10.4274/eajem.galenos.2025.23911
Poenou G, Dumitru Dumitru T, Lafaie L, et al. Pulmonary embolism in the cancer associated thrombosis landscape. J Clin Med. 2022;11(19):5650. doi:10.3390/jcm11195650
Park DY, An S, Kashoor I, Ezegwu O, Gupta S. In-hospital prognosis of malignancy-related pulmonary embolism: an analysis of the national inpatient sample 2016-2018. J Thromb Thrombolysis. 2022;54(4):630-638. doi:10.1007/s11239-022-02684-8
Zuin M, Nohria A, Henkin S, Krishnathasan D, Sato A, Piazza G. Pulmonary embolism-related mortality in patients with cancer. JAMA Netw Open. 2025;8(2):e2460315. doi:10.1001/jamanetworkopen.2024.60315
Agnelli G, Verso M. Management of venous thromboembolism in patients with cancer. J Thromb Haemost. 2011;9 Suppl 1:316-324. doi:10.1111/j.1538-7836.2011.04346.x

Li Y, Shang Y, Wang W, Ning S, Chen H. Lung cancer and pulmonary embolism: what is the relationship? A review. J Cancer. 2018;9(17):3046-3057. doi:10.7150/jca.26008
Zhang Y, Yang Y, Chen W, et al. Prevalence and associations of VTE in patients with newly diagnosed lung cancer. Chest. 2014;146(3):650-658. doi:10.1378/chest.13-2379
Sedhom R, Beshai R, Moussa P, et al. Outcomes with malignancy-associated high-risk pulmonary embolism: a nationwide analysis. Mayo Clin Proc. 2024;99(1):81-89. doi:10.1016/j.mayocp.2023.03.019
Lin YC, Chen SC, Huang CM, et al. Clinical features and diagnosis of new malignancy in patients with acute pulmonary embolism and without a history of cancer. J Chin Med Assoc. 2020;83(3):245-250. doi:10.1097/JCMA.0000000000000259
Wang Y, Liu Z, Li Q, et al. Prognosis of incidental pulmonary embolism vs. symptomatic pulmonary embolism in cancer patients: a single-center retrospective cohort study in China. Thromb J. 2023;21(1):64. doi:10.1186/s12959-023-00502-6
den Exter PL, Jiménez D, Kroft LJ, Huisman MV. Outcome of incidentally diagnosed pulmonary embolism in patients with malignancy. Curr Opin Pulm Med. 2012;18(5):399-405. doi:10.1097/MCP.0b013e3283553914
Wysokinska EM, Houghton DE, Vlazny DT, et al. Incidental pulmonary embolism in cancer and noncancer patients: prospective cohort study. Eur J Haematol. 2023;110(1):88-98. doi:10.1111/ejh.13877
Karamat A, Awan S, Hussain MG, Al Hameed F, Butt F, Wahla AS. Usefulness of clinical prediction rules, D-dimer, and arterial blood gas analysis to predict pulmonary embolism in cancer patients. Oman Med J. 2017;32(2):148-153. doi:10.5001/omj.2017.26
Kohn CG, Mearns ES, Parker MW, Hernandez AV, Coleman CI. Prognostic accuracy of clinical prediction rules for early post-pulmonary embolism all-cause mortality: a bivariate meta-analysis. Chest. 2015;147(4):1043-1062. doi:10.1378/chest.14-1888
Justyna A, Dzikowska-Diduch O, Pacho S, et al. Decreased haemoglobin level measured at admission predicts long term mortality after the first episode of acute pulmonary embolism. J Clin Med. 2022;11(23):7100. doi:10.3390/jcm11237100
Şener A, Sivri HÇ, Sivri S, et al. The prognostic value of the platelet/lymphocyte ratio in predicting short-term mortality in patients with acute pulmonary embolism. Sakarya Tıp Derg. 2015;5(4):204-208. doi:10.5505/sakaryamedj.2015.30164
Cohen AT, Katholing A, Rietbrock S, Bamber L, Martinez C. Epidemiology of first and recurrent venous thromboembolism in patients with active cancer. A population-based cohort study. Thromb Haemost. 2017;117(1):57-65. doi:10.1160/TH15-08-0686
Caliskan T, Turkoglu O, Canoglu K, et al. The comparison between non-high risk patients with and without cancer diagnosed with pulmonary embolism. Medeni Med J. 2021;36(1):30-35. doi:10.5222/MMJ.2021.43066

Details

Primary Language

English

Subjects

Respiratory Diseases

Journal Section

Research Article

Authors

Selda Günaydın ^*
0000-0001-5641-012X
Türkiye

Hayriye Bektaş Aksoy
0000-0002-4390-5198
Türkiye

Publication Date

July 16, 2026

Submission Date

April 26, 2026

Acceptance Date

May 23, 2026

Published in Issue

Year 2026 Volume: 8 Number: 4

IZ

https://izlik.org/JA64YB22NG

Cite

RIS / Bibtex

APA

Günaydın, S., & Bektaş Aksoy, H. (2026). Impact of malignancy on laboratory parameters and survival in patients with pulmonary embolism. Anatolian Current Medical Journal, 8(4), 625-630. https://izlik.org/JA64YB22NG

AMA

1.Günaydın S, Bektaş Aksoy H. Impact of malignancy on laboratory parameters and survival in patients with pulmonary embolism. Anatolian Curr Med J / ACMJ / acmj. 2026;8(4):625-630. https://izlik.org/JA64YB22NG

Chicago

Günaydın, Selda, and Hayriye Bektaş Aksoy. 2026. “Impact of Malignancy on Laboratory Parameters and Survival in Patients With Pulmonary Embolism”. Anatolian Current Medical Journal 8 (4): 625-30. https://izlik.org/JA64YB22NG.

EndNote

Günaydın S, Bektaş Aksoy H (July 1, 2026) Impact of malignancy on laboratory parameters and survival in patients with pulmonary embolism. Anatolian Current Medical Journal 8 4 625–630.

IEEE

[1]S. Günaydın and H. Bektaş Aksoy, “Impact of malignancy on laboratory parameters and survival in patients with pulmonary embolism”, Anatolian Curr Med J / ACMJ / acmj, vol. 8, no. 4, pp. 625–630, July 2026, [Online]. Available: https://izlik.org/JA64YB22NG

ISNAD

Günaydın, Selda - Bektaş Aksoy, Hayriye. “Impact of Malignancy on Laboratory Parameters and Survival in Patients With Pulmonary Embolism”. Anatolian Current Medical Journal 8/4 (July 1, 2026): 625-630. https://izlik.org/JA64YB22NG.

JAMA

1.Günaydın S, Bektaş Aksoy H. Impact of malignancy on laboratory parameters and survival in patients with pulmonary embolism. Anatolian Curr Med J / ACMJ / acmj. 2026;8:625–630.

MLA

Günaydın, Selda, and Hayriye Bektaş Aksoy. “Impact of Malignancy on Laboratory Parameters and Survival in Patients With Pulmonary Embolism”. Anatolian Current Medical Journal, vol. 8, no. 4, July 2026, pp. 625-30, https://izlik.org/JA64YB22NG.

Vancouver

1.Selda Günaydın, Hayriye Bektaş Aksoy. Impact of malignancy on laboratory parameters and survival in patients with pulmonary embolism. Anatolian Curr Med J / ACMJ / acmj [Internet]. 2026 Jul. 1;8(4):625-30. Available from: https://izlik.org/JA64YB22NG